机构:[1]The First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, PR China深圳市中医院深圳医学信息中心[2]Department of Oncology, Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, PR China深圳市中医院深圳医学信息中心[3]Department of Medical Technologic, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 518000, PR China[4]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 518000, PR China深圳市中医院深圳医学信息中心[5]Department of Oncology, Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, PR China广州中医药大学深圳医院深圳市康宁医院深圳医学信息中心[6]Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan 528000, Guangdong, PR China[7]Department of Psychiatry, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, PR China
Hepatocellular carcinoma (HCC) is characterized by rapid progression, high recurrence rate and poor prognosis. Early prediction for the prognosis and immunotherapy efficacy is of great significance to improve the survival of HCC patients. However, there is still no reliable predictor at present. This study is aimed to explore the role of centromere protein L (CENPL) in predicting prognosis and its association with immune infiltration in HCC.The expression of CENPL was identified through analyzing the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data. The association between CENPL expression and clinicopathological features was investigated by the Wilcoxon signed-rank test or Kruskal Wallis test and logistic regression. The role of CENPL in prognosis was examined via Kaplan-Meier method and Log-rank test as well as univariate and multivariate Cox regression analysis. Besides, in TIMER and GEPIA database, we investigated the correlation between CENPL level and immunocyte and immunocyte markers, and the prognostic-related methylation sites in CENPL were identified by MethSurv.CENPL had a high expression in HCC samples. Increased CENPL was prominently associated with unfavorable survival, and maybe an independent prognostic factor of worse overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), progression-free interval (PFI). Additionally, CENPL expression was significantly correlated with immune cell infiltration and some markers. CENPL also contained a methylation site that was notably related to poor prognosis.Elevated CENPL may be a promising prognostic marker and associate with immune infiltration in HCC.
基金:
Major research projects of Guangzhou University of Chinese Medicine in first-class disciplines (A1-AFD018181A29); Lingnan Traditional Chinese Medicine Tumor Academic School Inheritance Studio Project (No. 2016LP03).
第一作者机构:[1]The First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, PR China
共同第一作者:
通讯作者:
通讯机构:[2]Department of Oncology, Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, PR China[4]Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 518000, PR China[5]Department of Oncology, Shenzhen Hospital of Guangzhou University of Chinese Medicine, Shenzhen 518000, Guangdong, PR China
推荐引用方式(GB/T 7714):
Zhili Zeng,Xiao Jiang,Zhibin Pan,et al.Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma.[J].AGING-US.2021,13(19):22802-22829.doi:10.18632/aging.203574.
APA:
Zhili Zeng,Xiao Jiang,Zhibin Pan,Ruisheng Zhou,Zhuangteng Lin...&Zebiao Cao.(2021).Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma..AGING-US,13,(19)
MLA:
Zhili Zeng,et al."Highly expressed centromere protein L indicates adverse survival and associates with immune infiltration in hepatocellular carcinoma.".AGING-US 13..19(2021):22802-22829